Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$41.33 - $74.26 $824,740 - $1.48 Million
19,955 New
19,955 $843,000
Q1 2023

May 03, 2023

BUY
$47.19 - $70.77 $39,875 - $59,800
845 New
845 $57,000
Q2 2022

Aug 02, 2022

SELL
$35.61 - $76.23 $1.28 Million - $2.74 Million
-35,999 Reduced 90.4%
3,824 $151,000
Q1 2022

Apr 25, 2022

SELL
$57.56 - $82.54 $104,586 - $149,975
-1,817 Reduced 4.36%
39,823 $2.78 Million
Q4 2021

Feb 15, 2022

BUY
$72.5 - $100.68 $335,095 - $465,342
4,622 Added 12.49%
41,640 $3.24 Million
Q3 2021

Nov 12, 2021

SELL
$90.24 - $124.05 $4.47 Million - $6.14 Million
-49,516 Reduced 57.22%
37,018 $3.53 Million
Q2 2021

Aug 11, 2021

SELL
$93.66 - $139.27 $5.25 Million - $7.8 Million
-56,026 Reduced 39.3%
86,534 $10.8 Million
Q1 2021

May 11, 2021

BUY
$116.57 - $155.01 $4.25 Million - $5.66 Million
36,499 Added 34.41%
142,560 $18.8 Million
Q4 2020

Feb 03, 2021

BUY
$99.61 - $142.12 $9.42 Million - $13.4 Million
94,564 Added 822.51%
106,061 $14.1 Million
Q3 2020

Nov 12, 2020

BUY
$72.92 - $102.01 $838,361 - $1.17 Million
11,497 New
11,497 $1.17 Million
Q3 2019

Nov 12, 2019

SELL
$90.37 - $122.49 $53,499 - $72,514
-592 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$89.51 - $118.04 $126,746 - $167,144
-1,416 Reduced 70.52%
592 $70,000
Q1 2019

May 15, 2019

SELL
$61.98 - $96.5 $59,500 - $92,640
-960 Reduced 32.35%
2,008 $174,000
Q4 2018

Feb 11, 2019

BUY
$56.04 - $82.66 $166,326 - $245,334
2,968 New
2,968 $187,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Tobam Portfolio

Follow Tobam and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

News

Stay updated on Tobam with notifications on news.